Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Open Label, Randomized Two-Parallel-Arm Multicenter Study of E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes

NCT00337103 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT00337103
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00337103 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Open Label, Randomized Two-Parallel-Arm Multicenter Study of E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
Lead sponsor
Eisai Inc.
Phase
Phase 3
Overall status
Completed
Start date
September 20, 2006
Completion date
December 11, 2017
Enrollment
1,276 (actual)
Sites
169

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer